share_log

Reported Earlier, Roche's Genentech Announced Data From Stage 1 Of The National Institutes Of Health (NIH)-Sponsored Pivotal Phase III Outmatch Study Evaluating The Efficacy And Safety Ofxolair

Benzinga ·  Feb 26 03:11

– Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction –

– The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies –

– Allergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year –

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment